Skip To Main Content

Questions?1-833-393-4363

How VABYSMO may help in wet AMD

VABYSMO^® improves vision quickly and delivers a chance for up to 4 months between treatments

After 4 initial monthly doses. Your retina specialist will determine the dosing schedule that is right for you. Scroll down to learn more.

VABYSMO IMPROVES VISION QUICKLY

On average, people gained and maintained 6 letters on an eye chart in 1 year (chart)

On average, people gained and maintained 6 letters on an eye chart over 1 year with VABYSMO, similar to aflibercept 2 mg.

Even greater results of at least 15 letters were achieved by 20% of people taking VABYSMO, similar to aflibercept 2 mg.

VABYSMO helped people quickly gain some vision back after just 1 treatment*

Over 95% of people maintained their vision improvement
after 1 year with VABYSMO, similar to aflibercept 2 mg^†

Over 95% of people
maintained their vision improvement
after 1 year with VABYSMO, similar to aflibercept 2 mg^†

Icon representing drying of vision-damaging fluid in the eye

After 1 year of treatment, excess fluid in the eye decreased for most people^‡

Icon representing drying of vision-damaging fluid in the eye

After 1 year of treatment, excess fluid in the eye decreased for most people^‡

*After their first treatment, people on average gained 5 letters on an eye chart at 1 month with VABYSMO, similar to aflibercept 2 mg.

^†Maintained is defined as not losing 15 letters or more.

^‡In 2 clinical trials, VABYSMO was shown to reduce excess damaging fluid in the eye, similar to aflibercept 2 mg.

These results were not controlled for a possible type of statistical analysis error. Conclusions beyond the data shown should not be drawn.

VABYSMO was assessed in 2 clinical studies vs aflibercept 2 mg with 1329 people who were newly diagnosed with wet AMD.

*After their first treatment, people on average gained 5 letters on an eye chart at 1 month with VABYSMO, similar to aflibercept 2 mg.

^†Maintained is defined as not losing 15 letters or more.

^‡In 2 clinical trials, VABYSMO was shown to reduce excess damaging fluid in the eye, similar to aflibercept 2 mg.

These results were not controlled for a possible type of statistical analysis error. Conclusions beyond the data shown should not be drawn.

VABYSMO was assessed in 2 clinical studies vs aflibercept 2 mg with 1329 people who were newly diagnosed with wet AMD.

SEE A REAL-LIFE EXAMPLE OF HOW VABYSMO MAY HELP

BEFORE VABYSMO

OCT scan of eye before treatment

Before treatment, fluid builds up in the retina and can lead to vision loss.

WITH VABYSMO

OCT scan of eye after treatment

After 1 year of treatment with VABYSMO, the fluid has been reduced.

This patient was a participant with wet AMD receiving VABYSMO in clinical trials.

Patient experiences may vary.

No serious side effects in the eye were seen or reported for this person.

WITH VABYSMO, YOUR NEXT TREATMENT COULD BE 4 MONTHS AWAY

2-3-4 months between injections (graphic)

Although most people from the clinical trials went 3-4 months between injections, this may not be the experience of all people. Your retina specialist may evaluate your disease differently from the methods used in our trials.

After 4 initial monthly doses to stabilize your vision, your retina specialist may want to scan your eye or give you a vision test. These assessments will help determine if you can extend to 2-, 3-, or 4-month dosing.

VABYSMO gives you back some normalcy. We can plan things further out now and manage the things that come up.

Larry, a wet AMD patient being treated with VABYSMO since April 2022

Patient experiences may vary.

Watch Larry’s vision journey

A chance for up to 4 months injection-free

Patient experiences may vary.

A chance for up to 4 months injection-free

Patient experiences may vary.

We’re here to help

The Genentech Ophthalmology Support Line makes it easy for you to quickly access the information and support you need.

Just call (833) EYE-GENE/(833) 393-4363 and one of our representatives will be with you soon. Our representatives are available Monday to Friday, 9 am to 8 pm ET.

Sign up for the VABYSMO Patient Support Program and receive the VABYSMO Patient Welcome Kit.

SIGN UP FOR PATIENT SUPPORT

There may be options to help you afford VABYSMO. Find out what assistance you might be eligible for.

DISCOVER FINANCIAL SUPPORT

We’re here to help

The Genentech Ophthalmology Support Line makes it easy for you to quickly access the information and support you need.

Just call (833) EYE-GENE/(833) 393-4363 and one of our representatives will be with you soon. Our representatives are available Monday to Friday, 9 am to 8 pm ET.

Sign up for the VABYSMO Patient Support Program and receive the VABYSMO Patient Welcome Kit.

SIGN UP FOR PATIENT SUPPORT

There may be options to help you afford VABYSMO. Find out what assistance you might be eligible for.

DISCOVER FINANCIAL SUPPORT

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Do not receive VABYSMO if you:

Have an infection in or around your eye.
Have active swelling around your eye that may include pain and redness.
Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.
VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.

What should I avoid while receiving VABYSMO?

Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently.

What are the most common side effects with VABYSMO?

The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
These are not all the possible side effects of VABYSMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.

Please see the VABYSMO full Prescribing Information for additional Important Safety Information.